- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: AIDS-Related Lymphoma - March 2002
National Cancer Institute®
Last Modified: March 1, 2002
Table of Contents
1
UI - 11841403
AU - Wilson KS; McKenna RW; Kroft SH; Dawson DB; Ansari Q; Schneider NR
TI -
Primary effusion lymphomas exhibit complex and recurrent cytogenetic
abnormalities.
SO - Br J Haematol 2002 Jan;116(1):113-21
AD - Department of Pathology, University of Texas Southwestern Medical
Center, Dallas, TX 75390-9073, USA. wilson.kathleen@pathology.swmed.edu
Cytogenetic findings in a few primary effusion lymphoma (PEL) cell lines
have been reported, but only three complete karyotypes of primary
specimens from patients with this neoplasm have been published. In this
study, cytogenetic analysis was performed on 11 effusion specimens from
10 patients with PEL. We corroborate data obtained from the cell line
studies that trisomy 7, trisomy 12 and aberrations in the proximal long
arm of chromosome 1 (1q) are recurring cytogenetic aberrations in PEL
and also identify breakpoints at 3q23, 7p22, 7q22, 10q24, 12q24, 13q22,
14q24, 14q32, 15p11.2 and Xq22 as well as +8, +15, +19, +X and -Y as
recurring chromosome abnormalities. The identification of recurring
cytogenetic aberrations may lead to delineation of the genetic events in
PEL.
2
UI - 11682917
AU - Olatinwo TF; Herbowy MT; Hewitt RG
TI -
Toxoplasmic encephalitis and primary lymphoma of the brain--the shift in
epidemiology: a case series and review of the literature.
SO - AIDS Read 2001 Sep;11(9):444-9
AD - State University of New York at Buffalo, USA.
With the advent of HAART, there has been a decline in the incidence of
AIDS-defining illnesses. Despite this decline, we increasingly see
patients who present with AIDS-defining illnesses similar to those seen
during the early days of the HIV epidemic because patients are having
difficulty in tolerating or adhering to their HAART regimens. In
general, patients today are different: some are receiving prophylaxis to
prevent HIV-related infections and many have experienced a more
prolonged duration of immunosuppression resulting from intermittent use
of HAART. We present 4 patients with neurologic symptoms and focal brain
lesions and review and compare the diagnosis and treatment of
toxoplasmic encephalitis with that of primary CNS lymphoma.
3
UI - 11832678
AU - Vilchez RA; Lednicky JA; Halvorson SJ; White ZS; Kozinetz CA; Butel JS
TI -
Detection of polyomavirus simian virus 40 tumor antigen DNA in
AIDS-related systemic non-Hodgkin lymphoma.
SO - J Acquir Immune Defic Syndr 2002 Feb 1;29(2):109-16
AD - Department of Medicine, Baylor College of Medicine, Houston, Texas
77030, USA. rvilchez@bcm.tmc.edu
Systemic non-Hodgkin lymphoma (S-NHL) is a common malignancy during HIV
infection, and it is hypothesized that infectious agents may be involved
in the etiology. Epstein-Barr virus DNA is found in <40% of patients
with AIDS-related S-NHL, suggesting that other oncogenic viruses, such
as polyomaviruses, may play a role in pathogenesis. We analyzed
AIDS-related S-NHL samples, NHL samples from HIV-negative patients,
peripheral blood leukocytes from HIV-infected and -uninfected patients
without NHL, and lymph nodes without tumors from HIV-infected patients.
Specimens were examined by polymerase chain reaction analysis with use
of primers specific for an N-terminal region of the oncoprotein large
tumor antigen ( T-ag ) gene conserved among all three polyomaviruses
(simian virus 40 [SV40], JC virus, and BK virus). Polyomavirus T-ag DNA
sequences, proven to be SV40-specific, were detected more frequently in
AIDS-related S-NHL samples (6 of 26) than in peripheral blood leukocytes
from HIV-infected patients (6 of 26 vs. 0 of 69; p =.0001), NHL samples
from HIV-negative patients (6 of 26 vs. 0 of 10; p =.09), or lymph nodes
(6 of 26 vs. 0 of 7; p =.16). Sequences of C-terminal T-ag DNA from SV40
were amplified from two AIDS-related S-NHL samples. Epstein-Barr virus
DNA sequences were detected in 38% (10 of 26) AIDS-related S-NHL
samples, 50% (5 of 10) HIV-negative S-NHL samples, and 57% (4 of 7)
lymph nodes. None of the S-NHL samples were positive for both
Epstein-Barr virus DNA and SV40 DNA. Further studies of the possible
role of SV40 in the pathogenesis of S-NHL are warranted.
4
UI - 10989649
AU - Jhala DN; Medeiros LJ; Lopez-Terrada D; Jhala NC; Krishnan B; Shahab I
TI -
Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A
report of two cases arising in HIV-positive patients.
SO - Am J Clin Pathol 2000 Sep;114(3):478-82
AD - Department of Pathology, Ben Taub General Hospital, Houston, TX, USA.
Neutrophil-rich anaplastic large cell lymphoma (ALCL) is an uncommon
morphologic variant of ALCL. We report 2 cases of neutrophil-rich T-cell
ALCL that presented as scalp masses in HIV-positive men. Histologically,
the neoplastic cells extensively infiltrated the dermis and subcutaneous
tissue. The neoplastic cells strongly expressed CD30 and were of T-cell
lineage, positive for CD3 and CD45RO, and negative for CD20. The
neoplastic cells were negative for anaplastic lymphoma kinase-1.
Numerous admixed neutrophils also were present, representing up to 70%
of all cells in some microscopic fields. Neither patient had peripheral
blood leukocytosis. One patient had relative neutrophilia, 79% (0.79;
reference range, 50%-70% [0.50-0.70]). The absolute CD4 counts were 160
cells/microL (160 x 10(6)/L) and 150 cells/microL (150 x 10(6)/L),
respectively (reference range, 431-1,623/microL [431-1,623 x 10(6)/L]).
Both patients were treated with multiagent chemotherapy but died of
Pneumocystis carinii pneumonia within 6 months of diagnosis. In our
review of the literature, we identified 5 similar T-cell cases,
including 1 in an HIV-positive patient. Neutrophil-rich T-cell ALCL is a
rare morphologic variant of ALCL that should be considered in the
histologic evaluation of neutrophil-rich biopsy specimens.
5
UI - 11707651
AU - Al-Madi SH; Al-Obaid AM; El-Subbagh HI
TI -
The in vitro antitumor assay of 5-(Z)-arylidene-4-imidazolidinones in
screens of AIDS-related leukemia and lymphomas.
SO - Anticancer Drugs 2001 Nov;12(10):835-9
AD - Department of Pharmacology, College of Pharmacy, King Saud University,
PO Box 2457, Riyadh-11451, Saudi Arabia.
Thirty-one different 5-(Z)-arylidene-4-imidazolidinones were tested on
six AIDS-related lymphoma (ARL) tumor cell lines, one leukemia CCRF-CEM
cell culture and five different lymphoma cell lines: RL, KD-488, AS283,
PA682 and SU-DHL-7. The investigated compounds showed remarkable
activity against ARL, compounds 3d and 5c proved to inhibit AS283 and
SU-DHL-7 cell lines, respectively, both at a GI50 value of 0.03 microM.
The 2-(2-carboxyphenylamino) series proved to be the most active members
in this investigation. Compounds 6b and 6d showed GI50 (MGMID) values of
6.1 and 8.7 microM, respectively, against the studied six ARL.
6
UI - 11694949
AU - Wiernik PH
TI -
Treatment of human immunodeficiency virus-related lymphoma.
SO - Semin Hematol 2001 Oct;38(4 Suppl 10):27-31
AD - Our Lady of Mercy Comprehensive Cancer Center, New York Medical College,
Bronx, NY 10466, USA.
In newly diagnosed human immunodeficiency virus (HIV)-positive patients
with non-Hodgkin's lymphoma (NHL), standard lymphoma regimens yield
approximately a 50% complete response (CR) rate and an overall median
survival of < or = 9 months. Treatment results of relapsed patients are
extremely poor. Regimens that appear more effective than standard
therapy have usually been investigated only in patients with relatively
high CD4 counts. An exception is a regimen consisting of a continuous
96-hour infusion of cyclophosphamide, doxorubicin, and etoposide (CDE).
A 62% CR rate was achieved in 21 patients with a median CD4 count of
87/microL, and the median overall survival was 18 months. In another
study of 25 patients, didanosine (ddI) was added to CDE and was shown to
cause less myelosuppression without compromising efficacy. Other studies
suggest that highly active antiretroviral therapy (HAART) can be
combined with intensive chemotherapy regimens, with improved efficacy
attributed to less frequent dosage reduction of chemotherapeutic agents.
More recently, autologous and syngeneic bone marrow transplantation have
been explored in a handful of patients with acquired immunodeficiency
syndrome (AIDS)-related NHL with promising results. Data on whether
widespread use of HAART decreases the incidence of HIV-positive NHL are
conflicting. Some clues from recent studies suggest we are close to an
answer: (1) protease inhibitors significantly improve survival of
HIV-positive patients with NHL; (2) only one of eight recent cases of
HIV-positive men with NHL received HAART compared with greater than 70%
of HIV-positive men free of NHL; and (3) no prior HAART independently
predicted for AIDS-related NHL development. On the other hand, Hodgkin's
disease may be increasing in frequency in HIV-positive patients as the
incidence of NHL declines. It is hypothesized that more effective
reconstitution of the immune system with HAART may facilitate the
inversion of these incidences. Future prospective studies will hopefully
answer these questions. Copyright 2001 by W.B. Saunders Company.
7
UI - 11755462
AU - Tulpule A; Sherrod A; Dharmapala D; Young LL; Espina BM; Sanchez MN;
TI -
Gill PS; Levine AM
Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
SO - Leuk Res 2002 Feb;26(2):121-7
AD - Department of Medicine, University of Southern California Keck School of
Medicine, Los Angeles, CA, USA. tulpule@hsc.usc.edu
P-glycoprotein is a product of the multidrug resistance (MDR-1) gene. In
non-Hodgkin's lymphoma, less than 20% of untreated de novo lymphomas
express MDR-1 compared with approximately 50% after failure of
chemotherapy. We wished to study the expression of MDR-1 in AIDS-related
non-Hodgkin's lymphoma (AIDS-NHL). Tissue biopsies from 50 patients with
newly diagnosed AIDS-NHL were studied by immunohistochemical analysis
using C494, a monoclonal antibody specific for the MDR-1 isoform of
P-gp. MDR-1 expression was correlated with patient demographics,
lymphoma characteristics, response to chemotherapy, and survival.
Forty-six males and four females with a median age of 38 years (range
26-63) were studied. A prior AIDS-defining opportunistic infection was
reported in 35 patients (70%). The median CD4+ lymphocyte count was
69/mm(3) (range 0-920). Thirty-two patients (63%) had received prior
anti-HIV therapy, including a protease inhibitor in five (10%).
Pathologic types consisted of diffuse large cell in 13 (26%),
immunoblastic in 13 (26%), small non-cleaved in 22 (44%), and high grade
not otherwise specified in two (4%). The majority of patients (76%) had
stage III/IV disease. Pre-treatment lymphoma tissues from 33 patients
(66%) stained positively for MDR-1. MDR-1 positive patients had a
significantly lower complete remission rate compared to MDR-1 negative
patients (33 versus 65%, P=0.042). Duration of complete response was
significantly longer in MDR-1 negative patients compared with MDR-1
positive patients (not reached versus 9.9 months, P=0.003). Strategies
to overcome MDR-1 expression may be important for initial treatment in
patients with AIDS-NHL.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
